ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CREO Creo Medical Group Plc

16.625
0.50 (3.10%)
22 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Creo Medical Group Plc LSE:CREO London Ordinary Share GB00BZ1BLL44 ORD GBP0.001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 3.10% 16.625 16.50 16.75 16.625 16.00 16.125 1,054,480 15:14:22
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Surgical,med Instr,apparatus 30.8M -21.7M -0.0600 -2.77 58.29M

Creo Medical Group PLC Extension of Retail Offer Closing Date

04/10/2024 7:00am

RNS Regulatory News


RNS Number : 9065G
Creo Medical Group PLC
04 October 2024
 



THIS ANNOUNCEMENT, INLCUDING THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

 

THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF CREO MEDICAL GROUP PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY BY SUCH PERSONS.

 

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICIATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SECURITIES OF CREO MEDICAL GROUP PLC.

 

  

Creo Medical Group plc

("Creo" or the "Company")

 

Extension of Retail Offer Closing Date

 

Further to the announcement made on 30 September 2024 (RNS No 3043G) regarding the Retail Offer, the Company announces that it is extending the time allowed for existing retail shareholders to participate in the Retail Offer.

 

Under the revised timetable, the Retail Offer will now close at 4.30 p.m. on 17 October 2024 (previously 4.30 p.m. on 7 October). No other changes to the timetable have been made.

 

The change in timetable does not impact applications already made in the Retail Offer, and these continue to have effect and remain binding.

 

Revised Expected Timetable for the Fundraising

 

Latest time and date for receipt of Forms of Proxy and CREST voting instructions


10.00 a.m. on 16 October 2024

Closing of the Retail Offer and announcement of the result of the Retail Offer


4.30 p.m. on 17 October 2024

General Meeting


10.00 a.m. on 18 October 2024

Results of the General Meeting announced


18 October 2024

Admission of the New Ordinary Shares to trading on AIM and commencement of dealings


8.00 a.m. on 21 October 2024

Where applicable, expected date for CREST accounts to be credited in respect of New Ordinary Shares in uncertificated form


8.00 a.m. on 21 October 2024

Where applicable, expected date for despatch of definitive share certificates for New Ordinary Shares in certificated form


By 3 November 2024

 

For further information, please visit www.creomedical.com or contact:

 

Creo Medical Group plc

www.creomedical.com

 

Richard Rees (CFO)

+44 (0)1291 606 005

 



 

Cavendish Capital Markets Limited

(Nominated Adviser, Joint Bookrunner and Joint Broker)

 

+44 (0)20 7220 0500

 

Stephen Keys / Camilla Hume / George Lawson (NOMAD)


 

Michael Johnson (Sales)


 



 

Deutsche Numis (Joint Bookrunner and Joint Broker)

Freddie Barnfield / Duncan Monteith / Euan Brown

William Baunton (ECM)

+44 (0)20 7260 1000

 

 


 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

 

Paul McManus / Sam Allen /

Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

+44 (0)7867 984 082

 










 

Further information on the Company can be found on its website at: https://www.creomedical.com/en/investors/

 

The Company's LEI is 213800H188ZDCWWXFA21

 

This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.

 

Important Notices

The Retail Offer is only open to investors in the United Kingdom who fall within Article 43 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (which includes an existing member of the Company).

 

This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia (the "United States" or "US")), Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa, New Zealand or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction.

 

The Retail Offer Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or under the applicable state securities laws of the United States and may not be offered or sold directly or indirectly in or into the United States or to or for the account or benefit of any US person (within the meaning of Regulation S under the US Securities Act) (a "US Person"). No public offering of the Retail Offer Shares is being made in the United States. The Retail Offer Shares are being offered and sold outside the United States in "offshore transactions", as defined in, and in compliance with, Regulation S under the US Securities Act. In addition, the Company has not been, and will not be, registered under the US Investment Company Act of 1940, as amended.

 

This announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for Retail Offer Shares in the United States, Australia, Canada, New Zealand, Japan, the Republic of Ireland, the Republic of South Africa, New Zealand or any other jurisdiction in which such offer or solicitation is or may be unlawful. No public offer of the securities referred to herein is being made in any such jurisdiction.

 

The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

 

Each of Cavendish and Numis Securities Limited (t/a Deutsche Numis) ("Deutsche Numis") is authorised and regulated in the United Kingdom by the Financial Conduct Authority is acting exclusively for the Company and for no-one else and will not regard any other person (whether or not a recipient of this announcement) as its client in relation to the Retail Offer and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, nor for providing advice in connection with the Retail Offer, Admission and the other arrangements referred to in this announcement.

 

The value of Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market and currency movements. When you sell your investment, you may get back less than you originally invested. Figures refer to past performance and past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations.

 

Certain statements in this announcement are forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, assumptions and uncertainties that could cause the actual results of operations, financial condition, liquidity and dividend policy and the development of the industries in which the Company's businesses operate to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given those risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements.

 

These forward-looking statements speak only as at the date of this announcement and cannot be relied upon as a guide to future performance. Each of the Company, Cavendish and Deutsche Numis expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by the Financial Conduct Authority, the London Stock Exchange or applicable law.

 

The information in this announcement is for background purposes only and does not purport to be full or complete. None of Cavendish, Deutsche Numis or any of their respective affiliates, accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. Each of Cavendish, Deutsche Numis and their respective affiliates, accordingly disclaims all and any liability whether arising in tort, contract or otherwise which it might otherwise be found to have in respect of this announcement or its contents or otherwise arising in connection therewith.

 

Any indication in this announcement of the price at which the Ordinary Share have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser. No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings or target dividend per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings or dividends per share of the Company.

 

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement. The Retail Offer Shares to be issued or sold pursuant to the Retail Offer will not be admitted to trading on any stock exchange other than London Stock Exchange.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIBDGDSGDGSX

1 Year Creo Medical Chart

1 Year Creo Medical Chart

1 Month Creo Medical Chart

1 Month Creo Medical Chart

Your Recent History

Delayed Upgrade Clock